HHATL

Across TCGA pan-cancer cohorts, HHATL Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated HHATL data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher HHATL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HHATL expression acts as an unfavorable survival marker.

LUSC, READ, and BLCA are the cancer types where HHATL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.189	0.719	<.001	30	view →
READ	OS	Median	III,IV	0.428	0.759	.019	18	view →
BLCA	OS	Median	All	0.188	0.710	.004	15	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.209	0.659	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

HHATL–LUSC (DFS)

Open the LUSC breakdown →